
THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO
THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF KRM22 PLC IN ANY JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS ANNOUNCEMENT HAVE THE MEANINGS GIVEN TO THEM IN THE DEFINITIONS SECTION INCLUDED IN APPENDIX I.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION NO. 596/2014 AS IT FORMS PART OF
("KRM22", the "Company" or the "Group")
Result of Placing
The Fundraising has successfully raised gross proceeds of approximately
The Issue Price represents a discount of approximately 3.61% to the closing middle market price of an Ordinary Share on the day immediately preceding the Launch Announcement.
Notice of General Meeting and Shareholder Circular
As referred to in the Launch Announcement, the Company is seeking the approval of Shareholders for the allotment of the Fundraising Shares. The Company announces that it will therefore shortly despatch a circular to Shareholders of the Company to convene a General Meeting of the Company to be held at
Admission and Total Voting Rights
Subject to all resolutions being passed at the General Meeting, application will be made to the
The Fundraising Shares will be issued fully paid and will rank pari passu in all respects with the Existing Ordinary Shares.
Following Admission of the Fundraising Shares, the total number of Ordinary Shares in the capital of the Company in issue will be 59,269,490 with voting rights. This figure may be used by shareholders as the denominator for the calculations by which they will determine if or they are required to notify their interest in, or a change to their interest in, the Company's share capital pursuant to (i) the Company's Articles, (ii) the
Participation by Substantial Shareholders
Existing substantial Shareholders,
The Directors, having consulted with Cavendish, acting in its capacity as the Group's Nominated Adviser, consider the participation by
Capitalised terms used in this announcement have the meanings given to them in the Launch Announcement, unless context provides otherwise.
For further information please contact:
Dan Carter, CEO
Kim Suter, CFO
Sunila de Silva (ECM)
About
KRM22 is a closed-ended investment company which listed on AIM on
Through its investments and the Global Risk Platform, KRM22 helps capital market companies reduce the cost and complexity of risk management. The Global Risk Platform provides applications to help address firms' trading and corporate risk challenges and to manage their entire enterprise risk profile.
Capital markets companies' partner with KRM22 to optimise risk management systems and processes, improving profitability and expanding opportunities to increase portfolio returns by leveraging risk as alpha.
See more about KRM22 at www.krm22.com
Market Abuse Regulation
Market soundings, as defined in MAR, were taken in respect of the Placing, with the result that certain persons became aware of inside information, as permitted by MAR. That inside information is set out in this Announcement and has been disclosed as soon as possible in accordance with paragraph 7 of article 17 of MAR. Therefore, those persons that received inside information in a market sounding are no longer in possession of inside information relating to the Company and its securities.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the